The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.
 
Wenfeng Fang
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Jianjin Huang
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Benyan Zou
No Relationships to Disclose
 
Hongyun Zhao
No Relationships to Disclose
 
Yunpeng Yang
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Jing Zhao
No Relationships to Disclose
 
Lieming Ding
Employment - Betta Pharmaceuticals
Stock and Other Ownership Interests - Betta Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Betta Pharmaceuticals
 
Fenlai Tan
Employment - Betta Pharmaceuticals
Leadership - Betta Pharmaceuticals
Stock and Other Ownership Interests - Betta Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Betta Pharmaceuticals (Inst)
 
Li Zhang
No Relationships to Disclose